MX2023012515A - Tratamiento del cancer con un inhibidor de raf. - Google Patents
Tratamiento del cancer con un inhibidor de raf.Info
- Publication number
- MX2023012515A MX2023012515A MX2023012515A MX2023012515A MX2023012515A MX 2023012515 A MX2023012515 A MX 2023012515A MX 2023012515 A MX2023012515 A MX 2023012515A MX 2023012515 A MX2023012515 A MX 2023012515A MX 2023012515 A MX2023012515 A MX 2023012515A
- Authority
- MX
- Mexico
- Prior art keywords
- raf inhibitor
- cancer
- treatment
- compositions
- raf
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 102100025093 Zinc fingers and homeoboxes protein 2 Human genes 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 238000002648 combination therapy Methods 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163178922P | 2021-04-23 | 2021-04-23 | |
| PCT/US2022/025875 WO2022226261A1 (en) | 2021-04-23 | 2022-04-22 | Treatment of cancer with a raf inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023012515A true MX2023012515A (es) | 2023-12-15 |
Family
ID=83722622
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023012515A MX2023012515A (es) | 2021-04-23 | 2022-04-22 | Tratamiento del cancer con un inhibidor de raf. |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11918587B2 (https=) |
| EP (1) | EP4326256A4 (https=) |
| JP (1) | JP2024516972A (https=) |
| KR (1) | KR20240000534A (https=) |
| CN (1) | CN117561057A (https=) |
| AU (1) | AU2022261117A1 (https=) |
| BR (1) | BR112023021913A2 (https=) |
| CA (1) | CA3216104A1 (https=) |
| IL (1) | IL307908A (https=) |
| MX (1) | MX2023012515A (https=) |
| TW (1) | TW202308645A (https=) |
| WO (1) | WO2022226261A1 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112022007612A2 (pt) | 2019-10-24 | 2022-09-20 | Kinnate Biopharma Inc | Inibidores de raf quinases |
| WO2022081469A1 (en) | 2020-10-12 | 2022-04-21 | Kinnate Biopharma Inc. | Inhibitors of raf kinases |
| CN117561057A (zh) | 2021-04-23 | 2024-02-13 | 金耐特生物制药公司 | 用raf抑制剂治疗癌症 |
| AU2024265078A1 (en) | 2023-05-04 | 2025-12-11 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| IL326136A (en) | 2023-08-07 | 2026-03-01 | Revolution Medicines Inc | RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein |
| AU2024322235A1 (en) * | 2023-08-09 | 2026-02-26 | Pierre Fabre Medicament | Treatment of cancer with a raf inhibitor |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025145207A1 (en) * | 2023-12-29 | 2025-07-03 | Bristol-Myers Squibb Company | Combination therapy of kras inhibitor and treg-depleting agent |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6334997B1 (en) | 1994-03-25 | 2002-01-01 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
| CN1087725C (zh) | 1994-03-25 | 2002-07-17 | 同位素技术有限公司 | 用氘代方法增强药物效果 |
| US6187799B1 (en) | 1997-05-23 | 2001-02-13 | Onyx Pharmaceuticals | Inhibition of raf kinase activity using aryl ureas |
| US20070244120A1 (en) | 2000-08-18 | 2007-10-18 | Jacques Dumas | Inhibition of raf kinase using substituted heterocyclic ureas |
| GB9823873D0 (en) | 1998-10-30 | 1998-12-30 | Pharmacia & Upjohn Spa | 2-ureido-thiazole derivatives,process for their preparation,and their use as antitumour agents |
| WO2003068229A1 (en) | 2002-02-11 | 2003-08-21 | Bayer Pharmaceuticals Corporation | Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors |
| US7459562B2 (en) | 2004-04-23 | 2008-12-02 | Bristol-Myers Squibb Company | Monocyclic heterocycles as kinase inhibitors |
| US20070054916A1 (en) | 2004-10-01 | 2007-03-08 | Amgen Inc. | Aryl nitrogen-containing bicyclic compounds and methods of use |
| WO2006071940A2 (en) | 2004-12-23 | 2006-07-06 | Deciphera Pharmaceuticals, Llc | Enzyme modulators and treatments |
| US8188113B2 (en) | 2006-09-14 | 2012-05-29 | Deciphera Pharmaceuticals, Inc. | Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
| AR067354A1 (es) | 2007-06-29 | 2009-10-07 | Sunesis Pharmaceuticals Inc | Compuestos utiles como inhibidores de la raf quinasa |
| CA2714700C (en) | 2008-02-22 | 2013-07-30 | Irm Llc | Heterocyclic compounds and compositions as c-kit and pdgfr kinase inhibitors |
| EP2112150B1 (en) | 2008-04-22 | 2013-10-16 | Forma Therapeutics, Inc. | Improved raf inhibitors |
| WO2010078408A1 (en) | 2008-12-30 | 2010-07-08 | Biogen Idec Ma Inc. | Heteroaryl compounds useful as raf kinase inhibitors |
| AR090151A1 (es) | 2012-03-07 | 2014-10-22 | Lilly Co Eli | Compuestos inhibidores de raf |
| DK3366293T3 (da) | 2012-06-07 | 2020-06-15 | Deciphera Pharmaceuticals Llc | Dihydronaphthyridiner og relaterede forbindelser, der er nyttige som kinashæmmere til behandling af proliferative sygdomme |
| US9242969B2 (en) | 2013-03-14 | 2016-01-26 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
| US10167279B2 (en) | 2014-09-12 | 2019-01-01 | Novartis Ag | Compounds and compositions as RAF kinase inhibitors |
| UY36294A (es) | 2014-09-12 | 2016-04-29 | Novartis Ag | Compuestos y composiciones como inhibidores de quinasa |
| WO2020168172A1 (en) | 2019-02-15 | 2020-08-20 | Zamboni Chem Solutions Inc. | Conjugate compounds for the degradation of raf |
| JP2022525885A (ja) | 2019-03-22 | 2022-05-20 | キネート バイオファーマ インク． | Ｒａｆキナーゼの阻害剤 |
| US10927111B2 (en) * | 2019-05-03 | 2021-02-23 | Kinnate Biopharma Inc. | Inhibitors of RAF kinases |
| TWI891666B (zh) | 2019-10-14 | 2025-08-01 | 美商英塞特公司 | 作為ｆｇｆｒ抑制劑之雙環雜環 |
| BR112022007612A2 (pt) | 2019-10-24 | 2022-09-20 | Kinnate Biopharma Inc | Inibidores de raf quinases |
| US11407737B2 (en) * | 2020-09-18 | 2022-08-09 | Kinnate Biopharma Inc. | Inhibitors of RAF kinases |
| WO2022081469A1 (en) | 2020-10-12 | 2022-04-21 | Kinnate Biopharma Inc. | Inhibitors of raf kinases |
| CN117529313A (zh) | 2021-04-23 | 2024-02-06 | 金耐特生物制药公司 | 固态形式的(s)-n-(3-(2-(((r)-1-羟基丙-2-基)氨基)-6-吗啉代吡啶-4-基)-4-甲基苯基)-3-(2,2,2-三氟乙基)吡咯烷-1-甲酰胺及其盐 |
| CN117561057A (zh) * | 2021-04-23 | 2024-02-13 | 金耐特生物制药公司 | 用raf抑制剂治疗癌症 |
-
2022
- 2022-04-22 CN CN202280045318.4A patent/CN117561057A/zh active Pending
- 2022-04-22 AU AU2022261117A patent/AU2022261117A1/en active Pending
- 2022-04-22 JP JP2023565207A patent/JP2024516972A/ja active Pending
- 2022-04-22 MX MX2023012515A patent/MX2023012515A/es unknown
- 2022-04-22 WO PCT/US2022/025875 patent/WO2022226261A1/en not_active Ceased
- 2022-04-22 KR KR1020237039412A patent/KR20240000534A/ko active Pending
- 2022-04-22 BR BR112023021913A patent/BR112023021913A2/pt unknown
- 2022-04-22 CA CA3216104A patent/CA3216104A1/en active Pending
- 2022-04-22 TW TW111115522A patent/TW202308645A/zh unknown
- 2022-04-22 IL IL307908A patent/IL307908A/en unknown
- 2022-04-22 EP EP22792545.0A patent/EP4326256A4/en active Pending
-
2023
- 2023-04-06 US US18/296,726 patent/US11918587B2/en active Active
-
2024
- 2024-01-26 US US18/424,274 patent/US12569496B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP4326256A1 (en) | 2024-02-28 |
| US11918587B2 (en) | 2024-03-05 |
| BR112023021913A2 (pt) | 2024-01-16 |
| WO2022226261A1 (en) | 2022-10-27 |
| JP2024516972A (ja) | 2024-04-18 |
| EP4326256A4 (en) | 2025-03-19 |
| IL307908A (en) | 2023-12-01 |
| TW202308645A (zh) | 2023-03-01 |
| US12569496B2 (en) | 2026-03-10 |
| CA3216104A1 (en) | 2022-10-27 |
| US20240325403A1 (en) | 2024-10-03 |
| AU2022261117A1 (en) | 2023-11-23 |
| US20230255977A1 (en) | 2023-08-17 |
| CN117561057A (zh) | 2024-02-13 |
| KR20240000534A (ko) | 2024-01-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023012515A (es) | Tratamiento del cancer con un inhibidor de raf. | |
| CL2023000848A1 (es) | Terapia de combinación que incluye inhibidor de krasg12c y agente farmacéuticamente activo para tratar cáncer | |
| MX2023000735A (es) | Metodos y combinaciones de inhibidor de kat6 para el tratamiento del cancer. | |
| CO2020015255A2 (es) | Métodos y composiciones para tratar el cáncer | |
| NZ784224A (en) | Parp1 inhibitors | |
| MX2020008906A (es) | Compuestos con actividad inductora de ferroptosis y métodos de uso de estos. | |
| CL2018001152A1 (es) | Composiciones y métodos para el tratamiento del cáncer | |
| MX2019008158A (es) | Terapia de combinacion para el tratamiento del cancer. | |
| MX2021010173A (es) | Compuestos con actividad inductora de ferroptosis y métodos de uso. | |
| MX2022008099A (es) | Tratamiento para el cancer con inhibidores de cdk12/13. | |
| CL2024001678A1 (es) | Tratamiento del cáncer con un inhibidor de la cinasa fgfr | |
| MX2020001727A (es) | Terapia de combinacion. | |
| CL2021001623A1 (es) | Terapia de combinación con un inhibidor de raf y un inhibidor de cdk4/6 para utilizar en el tratamiento del cáncer | |
| PH12019500758A1 (en) | Pharmaceutical compositions and methods for the treatment of cancer | |
| CO2020010013A2 (es) | Terapia de combinación para tratar o prevenir el cáncer | |
| DOP2023000155A (es) | Tratamiento y terapia de mantenimiento para el cáncer de vejiga con gemcitabina | |
| MX386249B (es) | Terapia tusc2 para usarse en el tratamiento de cáncer. | |
| MX2019010981A (es) | Terapias de combinacion para el tratamiento de cancer de mama. | |
| MX2021015403A (es) | Terapia de combinacion que comprende un conjugado de anticuerpo-farmaco anti-cd19 y un inhibidor de pi3k o un agente secundario. | |
| MX2022011845A (es) | Terapia combinada con un inhibidor de idh mutante y un inhibidor de bcl-2. | |
| CL2023003090A1 (es) | Combinaciones de composiciones terapéuticas y usos para tratar cánceres | |
| CO2024001405A2 (es) | Composiciones y métodos para el tratamiento de cáncer | |
| MX2020008881A (es) | Métodos de tratamiento contra el cáncer que comprenden inhibidores de chk1. | |
| CL2023002812A1 (es) | Combinaciones farmacéuticas para el tratamiento del cáncer | |
| MX2022001450A (es) | Metodo de tratamiento del cancer. |